杨凯,杨明,苏学会,温辉,单娜
YANG Kai,YANG Ming,SU Xuehui,WEN Hui,SHAN Na

• 1:秦皇岛市第二医院呼吸科

摘要(Abstract)：

目的 通过生物信息学方法筛选出非小细胞肺癌（NSCLC）和对应的癌旁组织细胞的差异表达基因，寻找可能参与肺癌发生的关键基因，并分析其中关键基因与肺癌预后的关系。方法 根据人类肿瘤相关的基因表达汇编（GEO）中NSCLC组织和癌旁组织的表达谱芯片数据，以LogFC(Fold Change)绝对值> 1且P<0.01作为标准筛选差异表达基因；利用STRING数据库及Cytoscape软件构建蛋白质-蛋白质相互作者用（PPI）网络，筛选核心基因；选择核心基因中肺癌预后基因CAV1，利用肿瘤基因组图谱（TCGA）数据库分析核心基因与NSCLC患者的关系；收集100例NSCLC患者分为NSCLC组和癌旁组织组，检测两组组织中小窝蛋白1(Caveolin1)的表达情况。结果 根据GEO数据，在NSCLC组织和癌旁组织间共筛选出256个差异基因，其中上调的基因有206个，下调的基因有50个；PPI筛选出14个关键基因，选择CAV1基因开展后续研究；TCGA数据分析显示，NSCLC肿瘤组织中高表达CAV1的肿瘤患者生存期短于低表达CAV1的肿瘤患者（P<0.05）,NSCLC肿瘤组织中不同性别间CAV1基因表达量变化不明显（P> 0.05）,NSCLC肿瘤组织中CAV1表达量明显高于癌旁组织（P<0.01）,CAV1与MKI67、VIM的表达呈正相关（R=0.15、R=0.29,P<0.05）;NSCLC组中Caveolin1蛋白表达高于癌旁组织组（P<0.05）。结论 CAV1基因表达与NSCLC患者的生存期、肺癌增殖、转移等有关。
Objective To find the differentially expressed genes from non-small cell lung cancer(NSCLC) tissues and corresponding normal tissues, and analyze the relationship between the key genes and prognosis of NSCLC.Methods Based on the transcriptome data from gene expression omnibus( GEO), the differentially expressed genes from NSCLC tissues and corresponding normal tissues were screened according to the criteria of | LogFC( Fold Change) | > 1 andP< 0. 01. The STRING database and Cytoscape software were used to construct a protein-protein interaction(PPI)network and screen the core genes.CAV1 was selected and the prognosis was analyzed. The clinical data of 100 cases of NSCLC in our hospital were collected to analyze the expression of Caveolin-1 genes in paracancerous tissues and cancerous tissues.Results A total of 256 differentially expressed genes were screened between NSCLC tissues and corresponding normal tissues, including 206 up-regulated genes and 50 down-regulated genes. The PPI network analysis identified 14 key genes, including CAV1. The results from TCGA showed thatCAV1 was highly expressed in lung cancer tissues, and the survival time of patients with highCAV1 level was shorter(P<0.05). There was no significant change in CAV1 gene expression between different sexes in NSCLC turnor tissues(P> 0. 05).CAV1 expression in NSCLC tumor tissues was significantly higher than that in adjacent tissues(P< 0. 01). There was positive correlation betweenCAV1 expression andMKI67--VIMexpression(R= 0. 15,R= 0. 29,P< 0. 05). The expression of caveolinl protein in NSCLC tumor was hither than that in adjacent tissues(P< 0. 05).Conclusion CAV1 is closely related to the survival time, proliferation and metastasis of lung cancer.

关键词(KeyWords)： 非小细胞肺癌;小窝蛋白1;差异基因;CAV1;预后标志物;早期诊断
non-small cell lung cancer (NSCLC);caveolin-1;differential gene;CAV1;prognostic markers;early diagnosis

Abstract:

Keywords:

基金项目(Foundation): 河北省卫生和计划生育委员会科研基金（20191370）

作者(Author): 杨凯,杨明,苏学会,温辉,单娜
YANG Kai,YANG Ming,SU Xuehui,WEN Hui,SHAN Na

DOI: 10.19367/j.cnki.2096-8388.2022.06.008

参考文献(References)：

• [1] HUANG T T, LAN Y W, CHEN C M, et al.Antrodia cinnamomea induces anti-tumor activity by inhibiting the STAT3 signaling pathway in lung cancer cells[J]. Scientific Reports, 2019, 9(1):5145.
• [2] TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA:A Cancer Journal for Clinicians, 2015, 65(2):87-108.
• [3] ZHENG L, QI Y X, LIU S, et al. miR-129b suppresses cell proliferation in the human lung cancer cell lines A549and H1299[J]. Genetics and Molecular Research:GMR, 2016, 15(4):15048367.
• [4] SCOTT M G, LE ROUZIC E, PéRIANIN A, et al. Differential nucleocytoplasmic shuttling of beta-arrestins.Characterization of a leucine-rich nuclear export signal in beta-arrestin2[J]. The Journal of Biological Chemistry,2002, 277(40):37693-37701.
• [5] CEDRéS S, NU?EZ I, LONGO M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer(NSCLC)[J]. Clinical Lung Cancer, 2011, 12(3):172-179.
• [6] CHO A, HUR J, HONG Y J, et al. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer[J]. Tumor Biology, 2016, 37(3):3205-3213.
• [7] CHO W C. Contribution of oncoproteomics to cancer biomarker discovery[J]. Molecular Cancer, 2007, 6:25.
• [8] CHEN H Y, YU S L, LI K C, et al. Biomarkers and transcriptome profiling of lung cancer[J]. Respirology,2012, 17(4):620-626.
• [9] MOHAMED H, CLAY C J, CAROL C L, et al. The state of molecular biomarkers for the early detection of lung cancer[J]. Cancer Prevention Research(Philadelphia,Pa), 2012, 5(8):992-1006.
• [10]TORA?O E G, PETRUS S, FERNANDEZ A F, et al.Global DNA hypomethylation in cancer:review of validated methods and clinical significance[J]. Clinical Chemistry and Laboratory Medicine, 2012, 50(10):1733-1742.
• [11] INTERNATIONAL CANCER GENOME CONSORTIUM,HUDSON T J, ANDERSON W, et al. International network of cancer genome projects[J]. Nature, 2010, 464(7291):993-998.
• [12]DERISI J, PENLAND L, BROWN P O, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer[J]. Nature Genetics, 1996, 14(4):457-460.
• [13]LU T P, TSAI M H, LEE J M, et al. Identification of a novel biomarker,SEMA5A, for non–small cell lung carcinoma in nonsmoking women[J]. Cancer Epidemiology Biomarkers&Prevention, 2010, 19(10):2590-2597.
• [14] YASUMOTO K, HANAGIRI T, TAKENOYAMA M.Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer[J]. General Thoracic and Cardiovascular Surgery,2009, 57(9):449-457.
• [15]KOCATURK C I, GUNLUOGLU M Z, CANSEVER L, et al. Survival and prognostic factors in surgically resected synchronous multiple primary lung cancers[J]. European Journal of Cardio-Thoracic Surgery, 2011, 39(2):160-166.
• [16]CHEON D J, TONG Y G, SIM M S, et al. A collagenremodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer[J]. Clinical Cancer Research, 2014, 20(3):711-723.
• [17]SUN R C, WU J F, CHEN Y Y, et al. Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer[J]. Molecular Cancer, 2014,13:225.
• [18]WANG X, ZHANG L, LI H, et al. THBS2is a potential prognostic biomarker in colorectal cancer[J]. Scientific Reports, 2016, 6:33366.
• [19] ADAMS J C, LAWLER J. The thrombospondins[J].The International Journal of Biochemistry&Cell Biology,2004, 36(6):961-968.
• [20] RISHER W C, EROGLU C. Thrombospondins as key regulators of synaptogenesis in the central nervous system[J]. Matrix Biology, 2012, 31(3):170-177.
• [21] IRUELA-ARISPE M L, LUQUE A, LEE N. Thrombospondin modules and angiogenesis[J]. The International Journal of Biochemistry&Cell Biology, 2004, 36(6):1070-1078.
• [22]BORNSTEIN P. Thrombospondins function as regulators of angiogenesis[J]. Journal of Cell Communication and Signaling, 2009, 3(3/4):189-200.
• [23]ZHU J C, YAN T D, MORRIS D L. A systematic review of radiofrequency ablation for lung tumors[J]. Annals of Surgical Oncology, 2008, 15(6):1765-1774.
• [24]GALLUZZI L, VACCHELLI E, BRAVO-SAN PEDRO J M, et al. Classification of current anticancer immunotherapies[J]. Oncotarget, 2014, 5(24):12472-12508.
• [25]GOMES J, CRUZ M. Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors[J]. OncoTargets and Therapy, 2015:1137.
• [26]ROBINSON A G, YOUNG K, BALCHIN K, et al. Causes of death and subsequent treatment after initial radical or palliative therapy of stage III non-small-cell lung cancer[J]. Current Oncology, 2015, 22(5):333-340.
• [27]SATELLI A, LI S L. Vimentin in cancer and its potential as a molecular target for cancer therapy[J]. Cellular and Molecular Life Sciences, 2011, 68(18):3033-3046.

文章评论(Comment)：